Listed

CareCloud, Inc.: Form 10-Q for the period ended Sep 30, 2022

Filed with the SEC on Nov 3, 2022 and accepted by EDGAR at Nov 3, 2022, 16:31 ET.

Share

Management's discussion and analysis

As filed, 51,049 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following is a discussion of our consolidated financial condition and results of operations for the three and nine months ended September 30, 2022 and 2021, and other factors that are expected to affect our prospective financial condition. The following discussion and analysis should be read together with our Consolidated Financial Statements and related notes beginning on page 4 of this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 14, 2022.

Some of the statements set forth in this section are forward-looking statements relating to our future results of operations. Our actual results may vary from the results anticipated by these statements. Please see “Forward-Looking Statements” on page 2 of this Quarterly Report on Form 10-Q.

COVID-19 Pandemic

While the COVID-19 pandemic did not materially adversely affect the Company’s consolidated financial results and operations during the three and nine months ended September 30, 2022, economic and health conditions in the United States and across most of the globe continue to change.

The COVID-19 pandemic affected the Company’s operations in 2021 and may continue to do so indefinitely in the future. The pandemic may have an impact on the Company’s business, operations, and financial results and conditions, directly and indirectly, including, without limitation, impacts on the health of the Company’s management and employees, its operations, marketing and sales activities, and on the overall economy. The spread of the virus did not adversely affect the health and availability of our employees and staff. The scope and nature of these impacts, most of which are beyond the Company’s control, continue to evolve and the outcomes are uncertain.

Due to the above circumstances and as described generally in this Quarterly Report on Form 10-Q, the Company’s consolidated results of operations for the three and nine months ended September 30, 2022 may not necessarily be indicative of the results to be expected for the full fiscal year. The Company is not aware of any certain event or circumstance that would require an update to its estimates or judgements or a revision of the carrying value of its assets or liabilities as of the date of issuance of this Quarterly Report on Form 10-Q. These estimates could change in the future as new information about future developments is obtained. Management cannot predict the future impact of the COVID-19 pandemic on the Company’s consolidated operations nor on economic conditions generally, including the effects on patient visits. The ultimate extent of the effects of the COVID-19 pandemic on the Company is uncertain and will depend on highly unpredictable factors such as the ultimate geographic spread of the disease, the severity of the disease, the duration of outbreak, and the effectiveness of any further developments globally and nationally. The Company will actively monitor the situation and take further action that is in the best interest of our employees, customers, partners, and stockholders.

Overview

The Company is a healthcare information technology company that provides Software-as-a-Service offerings (“SaaS”) and technology-enabled business solutions, which are often bundled, but are occasionally provided individually, together with related business services to healthcare providers and hospitals throughout the United States. Our integrated SaaS platform includes revenue cycle management (“RCM”), practice management (“PM”), electronic health record (“EHR”), business intelligence, telehealth, patient experience management (“PXM”) solutions and complementary software tools and business services for high-performance medical groups and health systems.

At a high level, these solutions can be categorized as follows:

  • Technology-enabled business solutions, which are often bundled but are occasionally provided individually, including:
  • EHRs, which are easy to use, integrated with our business services or offered as Software-as-a-Service (“SaaS”) solutions, and allow our healthcare provider clients to deliver better patient care, document their clinical visits effectively and thus potentially qualify for government incentives, reduce documentation errors and reduce paperwork;
  • PM software and related tools, which support our clients’ day-to-day business operations and workflows;
  • Mobile Health (“mHealth”) solutions, including smartphone applications that assist patients and healthcare providers in the provision of healthcare services;
  • Telehealth solutions, which allow healthcare providers to conduct remote patient visits;
  • Chronic care management, which provides regular remote visits with patients with chronic conditions;
  • Healthcare claims clearinghouse, which enables our clients to electronically scrub and submit claims to, and process payments from, insurance companies;
  • Business intelligence, customized applications, interfaces and a variety of other technology solutions that support our healthcare clients;
  • RCM services, which include end-to-end medical billing, eligibility, analytics, and related services, all of which can often be provided either with our technology platform or through a third-party system; and
  • Professional services consisting of application and advisory services, revenue cycle services, data analytic services and educational training services.
  • Medical practice management services are provided to medical practices. In this service model, we provide the medical practice with appropriate facilities, equipment, supplies, support services, nurses and administrative support staff. We also provide management, bill-paying and financial advisory services.

Our solutions enable clients to increase financial and operational performance, streamline clinical workflows, get better insight through data, and make better business and clinical decisions, resulting in improvement in patient care and collections while reducing administrative burdens and operating costs.

The modernization of the healthcare industry is transforming nearly every aspect of a healthcare organization from policy to providers, clinical care to member services, devices to data, and ultimately the quality of the patient’s experience as a healthcare consumer. We create elegant, user-friendly applications that solve many of the challenges facing healthcare organizations. We partner with organizations to develop customized, best-in-class solutions to solve their specific challenges while ensuring they also meet future regulatory and organizational requirements and market demands.

We are able to deliver our industry-leading solutions at very competitive prices because we leverage a combination of our proprietary software, which automates our workflows and increases efficiency, together with our team of approximately 500 experienced health industry experts throughout the United States. These experts are supported by our highly educated and specialized offshore workforce of approximately 3,700 team members at labor costs that we believe are approximately one-tenth the cost of comparable U.S. employees. Our unique business model also allowed us to become a leading consolidator in our industry sector, gaining us a reputation for acquiring and positively transforming distressed competitors into profitable operations of CareCloud.

Adoption of our technology-enabled business solutions typically requires little or no upfront expenditure by a client. Additionally, for most of our solutions and customers, our financial performance is linked directly to the financial performance of our clients, as the vast majority of our revenues are based on a percentage of our clients’ collections. The fees we charge for our complete, integrated, end-to-end solution are very competitive and among the lowest in the industry. We estimate that we currently provide services to approximately 40,000 providers, (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services) practicing in approximately 2,600 independent medical practices and hospitals representing 80 specialties and subspecialties in 50 states. In addition, we serve approximately 200 clients that are not medical practices, but are primarily service organizations who serve the healthcare community. The foregoing numbers include clients leveraging any of our products or services, and are based, in part, upon estimates where the precise number of practices or providers is unknown.

We service clients ranging from small practices, consisting of one to ten providers, to large practices with over 2,300 providers operating in multiple states, to community hospitals.

On January 8, 2020, through a merger with a subsidiary, the Company acquired CareCloud Corporation, a Delaware corporation which was subsequently renamed CareCloud Health, Inc. (“CCH”), which has developed a highly acclaimed cloud-based platform including EHR, PM and patient experience capabilities. The Company paid $11.9 million in cash, assumed a working capital deficiency of approximately $5.1 million and issued 760,000 shares of the Company’s Series A Preferred Stock and two million warrants for the purchase of the Company’s common stock at prices of $7.50 for two years and $10.00 per share for three years.

On June 16, 2020, the Company purchased all of the issued and outstanding capital stock of Meridian Billing Management Co. and its affiliate Origin Holdings, Inc. (collectively, “Meridian,” and sometimes referred to as “Meridian Medical Management”), a former GE Healthcare IT company that delivers advanced healthcare information technology solutions and services. The Company paid $11.9 million in cash, issued 200,000 shares of the Company’s Series A Preferred Stock and warrants to purchase 2,250,000 of the Company’s common stock with an exercise price per share of $7.50 for two years and assumed Meridian’s negative working capital and certain long-term lease liabilities where the space is either not being utilized or will be vacated shortly, with an aggregate value of approximately $4.8 million.

On June 1, 2021, CareCloud Acquisition Corp (“CAC”), a wholly-owned subsidiary, entered into an Asset and Stock Purchase Agreement (the “Purchase Agreement”) with MedMatica Consulting Associates, Inc., (“MedMatica”) whereby CAC purchased the assets of MedMatica and the stock of its wholly-owned subsidiary Santa Rosa Staffing, Inc. (“SRS”). MedMatica and SRS provide a broad range of specialty consulting services to hospitals and large healthcare groups, including certain consulting services related to healthcare IT applications services and implementations, practice management, and revenue cycle management. The total consideration paid at closing was $10 million in cash, net of $1.5 million of escrow withheld. A working capital adjustment of approximately $3.8 million was also paid at closing. The Purchase Agreement provides that if during the 18-month period commencing on June 1, 2021 (“the “Earn-Out Period”), CAC’s EBITDA and revenue targets are achieved, then CAC shall pay an earn-out up to a maximum of $8 million (the “Base Earn-Out”). If during the Earn-Out Period, CAC’s additional and increased EBITDA and revenue targets are achieved, then CAC shall pay an additional earn-out, up to a maximum of $5 million (the “Additional Earn-Out”, collectively, with the Base Earn-Out, the “Earn-Out”). CAC will have the right to offset the Earn-Out against any claim for which CAC is entitled to indemnification under the Purchase Agreement and against damages for breaches by the seller of the non-competition and non-solicitation provisions in the Purchase Agreement.

Our offshore operations in the Pakistan Offices and Sri Lanka accounted for approximately 12% and 11% of total expenses for the nine months ended September 30, 2022 and 2021, respectively. A significant portion of those foreign expenses were personnel-related costs (approximately 80% for both the nine months ended September 30, 2022 and 2021). Because personnel-related costs are significantly lower in Pakistan and Sri Lanka than in the U.S. and many other offshore locations, we believe our offshore operations give us a competitive advantage over many industry participants. We are able to achieve significant cost reductions and leverage technology to reduce manual work and strategically transition a portion of the remaining manual tasks to our highly-specialized, cost-efficient team in the U.S., the Pakistan Offices and Sri Lanka.

Key Performance Measures

We consider numerous factors in assessing our performance. Key performance measures used by management, including adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share, are non-GAAP financial measures, which we believe better enable management and investors to analyze and compare the underlying business results from period to period.

These non-GAAP financial measures should not be considered in isolation, or as a substitute for or superior to, financial measures calculated in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Moreover, these non-GAAP financial measures have limitations in that they do not reflect all the items associated with the operations of our business as determined in accordance with GAAP. We compensate for these limitations by analyzing current and future results on a GAAP basis as well as a non-GAAP basis, and we provide reconciliations from the most directly comparable GAAP financial measures to the non-GAAP financial measures. Our non-GAAP financial measures may not be comparable to similarly titled measures of other companies. Other companies, including companies in our industry, may calculate similarly titled non-GAAP financial measures differently than we do, limiting the usefulness of those measures for comparative purposes.

Adjusted EBITDA, adjusted operating income, adjusted operating margin, adjusted net income and adjusted net income per share provide an alternative view of performance used by management and we believe that an investor’s understanding of our performance is enhanced by disclosing these adjusted performance measures.

Adjusted EBITDA excludes the following elements which are included in GAAP net income (loss):

  • Income tax expense (benefit) or the cash requirements to pay our taxes;
  • Interest expense, or the cash requirements necessary to service interest on principal payments, on our debt;
  • Foreign currency gains and losses and other non-operating expenditures;
  • Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
  • Depreciation and amortization charges;
  • Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
  • Net loss on lease termination, impairment and unoccupied lease charges; and
  • Change in contingent consideration.

Set forth below is a presentation of our adjusted EBITDA for the three and nine months ended September 30, 2022 and 2021:

($ in thousands)

Three Months Ended September 30, 2022 2021 Nine Months Ended September 30, 2022 2021
Net revenue $33,723 $38,304 $106,292 $102,137
GAAP net income (loss) 1,056 1,505 4,933 (686)
Provision (benefit) for income taxes 55 (232) 144 (20)
Net interest expense 82 87 281 264
Foreign exchange loss / other expense 523 70 359 167
Stock-based compensation expense 1,328 1,004 3,399 4,006
Depreciation and amortization 2,810 3,547 8,686 9,505
Transaction and integration costs 316 269 724 1,118
Net loss on lease termination, impairment and unoccupied lease charges 307 424 928 1,664
Change in contingent consideration (1,660) - (2,890) -
Adjusted EBITDA $4,817 $6,674 $16,564 $16,018

29

Adjusted operating income and adjusted operating margin exclude the following elements that are included in GAAP operating income (loss):

  • Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
  • Amortization of purchased intangible assets;
  • Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
  • Net loss on lease termination, impairment and unoccupied lease charges; and
  • Change in contingent consideration.

Set forth below is a presentation of our adjusted operating income and adjusted operating margin, which represents adjusted operating income as a percentage of net revenue, for the three and nine months ended September 30, 2022 and 2021:

($ in thousands)

Three Months Ended September 30, 2022 2021 Nine Months Ended September 30, 2022 2021
Net revenue $33,723 $38,304 $106,292 $102,137
GAAP net income (loss) 1,056 1,505 4,933 (686)
Provision (benefit) for income taxes 55 (232) 144 (20)
Net interest expense 82 87 281 264
Other expense - net 495 65 300 80
GAAP operating income (loss) 1,688 1,425 5,658 (362)
GAAP operating margin 5.0% 3.7% 5.3% (0.4)%
Stock-based compensation expense 1,328 1,004 3,399 4,006
Amortization of purchased intangible assets 1,428 2,768 4,884 7,079
Transaction and integration costs 316 269 724 1,118
Net loss on lease termination, impairment and unoccupied lease charges 307 424 928 1,664
Change in contingent consideration (1,660) - (2,890) -
Non-GAAP adjusted operating income $3,407 $5,890 $12,703 $13,505
Non-GAAP adjusted operating margin 10.1% 15.4% 12.0% 13.2%

Adjusted net income and adjusted net income per share exclude the following elements which are included in GAAP net income (loss):

  • Foreign currency gains and losses and other non-operating expenditures;
  • Stock-based compensation expense includes cash-settled awards and the related taxes, based on changes in the stock price;
  • Amortization of purchased intangible assets;
  • Integration costs, such as severance amounts paid to employees from acquired businesses, and transaction costs, such as brokerage fees, pre-acquisition accounting costs and legal fees and exit costs related to contractual agreements;
  • Net loss on lease termination, impairment and unoccupied lease charges;
  • Change in contingent consideration; and
  • Income tax expense (benefit) resulting from the amortization of goodwill related to our acquisitions.

No tax effect has been provided in computing non-GAAP adjusted net income and non-GAAP adjusted net income per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes. The following table shows our reconciliation of GAAP net loss to non-GAAP adjusted net income for the three and nine months ended September 30, 2022 and 2021:

($ in thousands)

Three Months Ended September 30, 2022 2021 Nine Months Ended September 30, 2022 2021
GAAP net income (loss) $1,056 $1,505 $4,933 $(686)
Foreign exchange loss / other expense 523 70 359 167
Stock-based compensation expense 1,328 1,004 3,399 4,006
Amortization of purchased intangible assets 1,428 2,768 4,884 7,079
Transaction and integration costs 316 269 724 1,118
Net loss on lease termination, impairment and unoccupied lease charges 307 424 928 1,664
Change in contingent consideration (1,660) - (2,890) -
Income tax expense related to goodwill 35 13 61 140
Non-GAAP adjusted net income $3,333 $6,053 $12,398 $13,488

Set forth below is a reconciliation of our GAAP net loss attributable to common shareholders, per share to our non-GAAP adjusted net income per share:

Three Months Ended September 30, 2022 2021 Nine Months Ended September 30, 2022 2021
GAAP net loss attributable to common shareholders, per share $(0.18) $(0.15) $(0.45) $(0.77)
Impact of preferred stock dividend 0.25 0.25 0.78 0.72
Net income (loss) per end-of-period share 0.07 0.10 0.33 (0.05)
Foreign exchange loss / other expense 0.03 0.00 0.02 0.01
Stock-based compensation expense 0.09 0.07 0.23 0.27
Amortization of purchased intangible assets 0.09 0.19 0.31 0.48
Transaction and integration costs 0.02 0.02 0.05 0.08
Net loss on lease termination, impairment and unoccupied lease charges 0.02 0.03 0.06 0.11
Change in contingent consideration (0.11) 0.00 (0.19) 0.00
Income tax expense related to goodwill 0.00 0.00 0.00 0.01
Non-GAAP adjusted earnings per share $0.21 $0.41 $0.81 $0.91
End-of-period common shares 15,211,136 14,873,411 15,211,136 14,873,411
In-the-money warrants and outstanding unvested RSUs 605,526 2,432,636 605,526 2,432,636
Total fully diluted shares 15,816,662 17,306,047 15,816,662 17,306,047
Non-GAAP adjusted diluted earnings per share $0.21 $0.35 $0.78 $0.78

For purposes of determining non-GAAP adjusted earnings per share, the Company used the number of common shares outstanding at the end of September 30, 2022 and 2021. Non-GAAP adjusted diluted earnings per share was computed using an as-converted method and includes warrants that are in-the-money as of that date as well as outstanding unvested RSUs. Non-GAAP adjusted earnings per share and non-GAAP adjusted diluted earnings per share do not take into account dividends paid on Preferred Stock. No tax effect has been provided in computing non-GAAP adjusted earnings per share and non-GAAP adjusted diluted earnings per share as the Company has sufficient carry forward net operating losses to offset the applicable income taxes.

Key Metrics

In addition to the line items in our consolidated financial statements, we regularly review the following metrics. We believe information on these metrics is useful for investors to understand the underlying trends in our business.

Providers and Practices Served: As of both September 30, 2022 and 2021, we provided services to an estimated universe of approximately 40,000 providers (which we define as physicians, nurses, nurse practitioners, physician assistants and other clinical staff that render bills for their services), representing approximately 2,600 independent medical practices and hospitals. In addition, we served approximately 200 clients who were not medical practices, but are service organizations who serve the healthcare community. The foregoing numbers include clients leveraging any of our products or services and are based in part upon estimates in cases where the precise number of practices or providers is unknown.

Sources of Revenue

Revenue: We primarily derive our revenues from subscription-based technology-enabled business solutions, reported in our Healthcare IT segment, which are typically billed as a percentage of payments collected by our customers. This fee includes RCM, as well as the ability to use our EHR, practice management system and other software as part of the bundled fee. These solutions accounted for approximately 64% and 71% of our revenues during the three months ended September 30, 2022 and 2021, respectively, and 64% and 78% for the nine months ended September 30, 2022 and 2021, respectively. Other healthcare IT services, including printing and mailing operations, group purchasing and professional services, represented approximately 25% and 20% of revenues for the three months ended September 30, 2022 and 2021, respectively, and 26% and 13% for the nine months ended September 30, 2022 and 2021, respectively.

We earned approximately 11% and 9% of our revenue from medical practice management services during the three months ended September 30, 2022 and 2021, respectively, and 10% and 9% for the nine months ended September 30, 2022 and 2021, respectively. This revenue represents fees based on our actual costs plus a percentage of the operating profit and is reported in our Medical Practice Management segment.

Operating Expenses

Direct Operating Costs. Direct operating cost consists primarily of salaries and benefits related to personnel who provide services to our customers, claims processing costs, costs to operate the three managed practices, including facility lease costs, supplies, insurance and other direct costs related to our services. Costs associated with the implementation of new customers are expensed as incurred. The reported amounts of direct operating costs do not include depreciation and amortization, which are broken out separately in the consolidated statements of operations.

Selling and Marketing Expense. Selling and marketing expense consists primarily of compensation and benefits, commissions, travel and advertising expenses.

General and Administrative Expense. General and administrative expense consists primarily of personnel-related expense for administrative employees, including compensation, benefits, travel, facility lease costs and insurance, software license fees and outside professional fees.

Research and Development Expense. Research and development expense consists primarily of personnel-related costs, software expense and third-party contractor costs.

Contingent Consideration. Contingent consideration represents the portion of consideration payable to the sellers of some of our acquisitions, the amount of which is based on the achievement of defined performance measures contained in the purchase agreements. Contingent consideration is adjusted to fair value at the end of each reporting period.

Depreciation and Amortization Expense. Depreciation expense is charged using the straight-line method over the estimated lives of the assets ranging from three to five years. Amortization expense is charged on either an accelerated or on a straight-line basis over a period of three or four years for most intangible assets acquired in connection with acquisitions including those intangibles related to the group purchasing services. Amortization expense related to the value of our medical practice management clients is amortized on a straight-line basis over a period of twelve years.

Net Loss on Lease Termination, Impairment and Unoccupied Lease Charges. Net loss on lease termination represents the write-off of leasehold improvements and gains or losses as the result of lease terminations. Impairment charges represent charges recorded for a leased facility no longer being used by the Company and a non-cancellable vendor contract where the services are no longer being used. Unoccupied lease charges represent the portion of lease and related costs for vacant space not being utilized by the Company.

Interest and Other Income (Expense). Interest expense consists primarily of interest costs related to our line of credit, term loans and amounts due in connection with acquisitions, offset by interest income. Other income (expense) results primarily from foreign currency transaction gains (losses) and income earned from temporary cash investments.

Income Tax. In preparing our consolidated financial statements, we estimate income taxes in each of the jurisdictions in which we operate. This process involves estimating actual current tax exposure together with assessing temporary differences resulting from differing treatment of items for tax and financial reporting purposes. These differences result in deferred income tax assets and liabilities. Although the Company is forecasting a return to profitability, it incurred losses historically and there is uncertainty regarding future U.S. taxable income, which makes realization of a deferred tax asset difficult to support in accordance with ASC 740. Accordingly, a valuation allowance has been recorded against all deferred tax assets as of September 30, 2022 and December 31, 2021.

Critical Accounting Policies and Estimates

The critical accounting policies and estimates used in the preparation of our consolidated financial statements that we believe affect our more significant judgments and estimates used in the preparation of our consolidated financial statements presented in this Report are described in Management’s Discussion and Analysis of Financial Condition and Results of Operations and in the Notes to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2021.

Leases:

We determine if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, operating lease liability (current portion) and operating lease liability (noncurrent portion) in the consolidated balance sheets at September 30, 2022 and December 31, 2021. The Company does not have any finance leases.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.

We use our estimated incremental borrowing rates, which are derived from information available at the lease commencement date, in determining the present value of lease payments. We give consideration to bank financing arrangements, geographical location and collateralization of assets when calculating our incremental borrowing rates.

Our lease term includes options to extend the lease when it is reasonably certain that we will exercise that option. Leases with a term of less than 12 months are not recorded in the consolidated balance sheet. Our lease agreements do not contain any residual value guarantees. For real estate leases, we account for the leased and non-leased components as a single lease component. Some leases include escalation clauses and termination options that are factored into the determination of the future lease payments when appropriate.

Capitalized Software Costs:

All of our software is considered internal use for accounting purposes, as we do not market or sell our software. As a result, we capitalize certain costs associated with the creation of internally-developed software for internal use. The total of these costs is recorded in Intangible assets – net in our consolidated balance sheets.

We capitalized costs incurred during the application development stage related to our internal use software. Costs incurred during the application development phase are capitalized only when we believe it is probable that the development will result in new or additional functionality. The types of costs capitalized during the application development phase consist of employee compensation, employee benefits and employee stock-based compensation. Costs related to the preliminary project stage and post-implementation activities are expensed as incurred. Capitalized internal-use software is amortized on a straight-line basis over its estimated useful life when the asset has been placed in service for general availability.

Significant judgments related to internally-developed software include determining whether it is probable that projects will result in new or additional functionality; concluding on when the application development phase starts and ends; and deciding which costs, especially employee compensation costs, should be capitalized. Additionally, there is judgment applied to the useful lives of capitalized software; we have concluded that the useful lives for capitalized internally-developed software is three years.

Company management employs its best estimates and assumptions in determining the appropriateness of the judgments noted above on a project-by-project basis during initial capitalization as well as subsequent measurement. While we believe that our approach to estimates and judgments is reasonable, actual results could differ, and such differences could lead to an increase or decrease in expense.

As of September 30, 2022 and December 31, 2021, the carrying amounts of internally-developed capitalized software in use was $15.5 million and $11.6 million, respectively. The increase in the capitalized software costs represents the continued investment in proprietary technology.

There have been no material changes in our critical accounting policies and estimates from those described in the Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 14, 2022.

Results of Operations

The following table sets forth our consolidated results of operations as a percentage of total revenue for the periods shown:

Three Months Ended September 30, 2022 2021 Nine Months Ended September 30, 2022 2021
Net revenue 100.0% 100.0% 100.0% 100.0%
Operating expenses:
Direct operating costs 60.5% 63.0% 61.0% 61.4%
Selling and marketing 7.4% 6.2% 6.9% 6.3%
General and administrative 19.3% 15.5% 17.4% 17.4%
Research and development 3.5% 1.3% 3.1% 4.2%
Change in contingent consideration (4.9)% 0.0% (2.7)% 0.0%
Depreciation and amortization 8.3% 9.3% 8.2% 9.3%
Net loss on lease termination, impairment and unoccupied lease charges 0.9% 1.1% 0.9% 1.6%
Total operating expenses 95.0% 96.4% 94.8% 100.2%
Operating income (loss) 5.0% 3.6% 5.2% (0.2)%
Interest expense - net 0.2% 0.2% 0.3% 0.3%
Other expense - net (1.5)% (0.2)% (0.3)% (0.1)%
Income (loss) before provision (benefit) for income taxes 3.3% 3.2% 4.6% (0.6)%
Income tax provision (benefit) 0.2% (0.6)% 0.1% (0.0)%
Net income (loss) 3.1% 3.8% 4.5% (0.6)%

Comparison of the three and nine months ended September 30, 2022 and 2021:

($ in thousands)

Three Months Ended September 30, 2022 2021 Change Amount Percent Nine Months Ended September 30, 2022 2021 Change Amount Percent
Net revenue $33,723 $38,304 $(4,581) (12%) $106,292 $102,137 $4,155 4%

Net Revenue. Net revenue of $33.7 million and $106.3 million for the three and nine months ended September 30, 2022 decreased by $4.6 million or 12% and increased by $4.2 million or 4% from net revenue of $38.3 million and $102.1 million for the three and nine months ended September 30, 2021, respectively. Revenue for the three and nine months ended September 30, 2022 includes approximately $6.4 million and $22.2 million from customers acquired in the medSR acquisition, offset primarily by a decrease in revenue from three large accounts from a 2020 acquisition that are winding down. Revenue for the three and nine months ended September 30, 2022 includes $21.6 million and $68.5 million relating to technology-enabled business solutions, $7.4 million and $25.6 million related to professional services and $3.8 million and $10.1 million for medical practice management services.

($ in thousands)

Three Months Ended September 30, 2022 2021 Change Amount Percent Nine Months Ended September 30, 2022 2021 Change Amount Percent
Direct operating costs $20,406 $24,124 $(3,718) (15%) $64,866 $62,719 $2,147 3%
Selling and marketing 2,504 2,375 129 5% 7,314 6,469 845 13%
General and administrative 6,500 5,921 579 10% 18,479 17,814 665 4%
Research and development 1,168 488 680 139% 3,251 4,328 (1,077) (25%)
Change in contingent consideration (1,660) - (1,660) N/A (2,890) - (2,890) N/A
Depreciation 474 488 (14) (3%) 1,405 1,482 (77) (5%)
Amortization 2,336 3,059 (723) (24%) 7,281 8,023 (742) (9%)
Net loss on lease termination, impairment and unoccupied lease charges 307 424 (117) (28%) 928 1,664 (736) (44%)
Total operating expenses $32,035 $36,879 $(4,844) (13%) $100,634 $102,499 $(1,865) (2%)

Direct Operating Costs. Direct operating costs of $20.4 million and $64.9 million for the three and nine months ended September 30, 2022 decreased by $3.7 million or 15% and increased by $2.1 million or 3% compared to direct operating costs of $24.1 million and $62.7 million for the three and nine months ended September 30, 2021, respectively. During the three and nine months ended September 30, 2022, salary costs decreased by $3.3 million and $894,000, and outsourcing and processing costs decreased by $456,000 and increased by $2.9 million, respectively. The decrease in the salary costs was due to the decrease in the Pakistan exchange rate, a decrease in the US headcount and the redeployment of employees performing functions that were classified as direct operating costs to functions classified as research and development expense for the three and nine months ended September 30, 2022.

Selling and Marketing Expense. Selling and marketing expense of $2.5 million and $7.3 million for the three and nine months ended September 30, 2022 increased by $129,000 or 5% and $845,000 or 13% from selling and marketing expense of $2.4 million and $6.5 million for the three and nine months ended September 30, 2021. The increase was primarily related to additional emphasis on sales and marketing activities.

General and Administrative Expense. General and administrative expense of $6.5 million and $18.5 million for the three and nine months ended September 30, 2022 increased by $579,000 or 10% and $665,000 or 4% compared to general and administrative expense of $5.9 million and $17.8 million for the three and nine months ended September 30, 2021. The increase is primarily due to the Company’s contributions to community based projects and to a new academic institution in the Bagh area, a community where the Company has a large employee base.

Research and Development Expense. Research and development expense of $1.2 million and $3.3 million for the three and nine months ended September 30, 2022 increased by approximately $680,000 and decreased by $1.1 million from research and development expense of $488,000 and $4.3 million for the three and nine months ended September 30, 2021. The decrease represents less maintenance work on platforms generating revenue and more resources dedicated to development of new technology which is not yet in commercial use and the increase is due to the redeployment of employees performing functions that were classified as direct operating costs to functions classified as research and development expense. During the nine months ended September 30, 2022 and 2021, the Company capitalized approximately $7.0 million and $5.3 million, respectively, of development costs in connection with its internal-use software. For the three months ended September 30, 2022 and 2021, the Company capitalized approximately $2.3 million and $2.0 million, respectively, of such costs.

Change in Contingent Consideration. The change of $1.7 million and $2.9 million for the three and nine months ended September 30, 2022 reflects the estimated decrease in the fair value of the contingent consideration from the medSR acquisition.

Depreciation. Depreciation of $474,000 and $1.4 million for the three and nine months ended September 30, 2022, respectively, decreased by $14,000 or 3% and $77,000 or 5% from the depreciation of $488,000 and $1.5 million for the three and nine months ended September 30, 2021, respectively.

Amortization Expense. Amortization expense of $2.3 million and $7.3 million for the three and nine months ended September 30, 2022, respectively, decreased by $723,000 or 24% and $742,000 or 9% from amortization expense of $3.1 million and $8.0 million for the three and nine months ended September 30, 2021, respectively. The decrease in amortization expense was due to intangibles which were previously capitalized becoming fully amortized.

Net Loss on Lease Termination, Impairment and Unoccupied Lease Charges. Net loss on lease termination represents the write-off of leasehold improvements and gains or losses as the result of lease terminations. During the nine months ended September 30, 2022, a facility lease was terminated in conjunction with the Company ceasing its document storage services resulting in additional costs of approximately $248,000. Impairment charges represent charges recorded for a leased facility no longer being used by the Company and a non-cancellable vendor contract where the services are no longer being used. Unoccupied lease charges represent the portion of lease and related costs for that portion of the space that is vacant and not being utilized by the Company. The Company was able to turn back to the landlord one of the unused facilities effective January 1, 2022.

($ in thousands)

Three Months Ended September 30, 2022 2021 Change Amount Percent Nine Months Ended September 30, 2022 2021 Change Amount Percent
Interest income $14 $4 $10 250% $22 $10 $12 120%
Interest expense (96) (91) (5) (5%) (303) (274) (29) (11%)
Other expense - net (495) (65) (430) (662%) (300) (80) (220) (275%)
Income tax provision (benefit) 55 (232) (287) (124%) 144 (20) (164) (820%)

Interest Income. Interest income of $14,000 and $22,000 for the three and nine months ended September 30, 2022 increased by $10,000 or 250% and $12,000 or 120% from interest income of $4,000 and $10,000 for the three and nine months ended September 30, 2021. The interest income represents interest earned on temporary cash investments.

Interest Expense. Interest expense of $96,000 and $303,000 for the three and nine months ended September 30, 2022 increased by $5,000 or 5% and $29,000 or 11% from interest expense of $91,000 and $274,000 for the three and nine months ended September 30, 2021. Interest expense includes the amortization of deferred financing costs, which was $92,000 and $107,000 during the nine months ended September 30, 2022 and 2021, respectively.

Other Expense – net. Other expense – net was $495,000 and $300,000 for the three and nine months ended September 30, 2022 compared to other expense – net of $65,000 and $80,000 for the three and nine months ended September 30, 2021. Other expense primarily represents foreign currency transaction gains and losses. These transaction gains and losses result from revaluing intercompany accounts whenever the exchange rate varies and are recorded in the consolidated statements of operations.

Income Tax Provision (Benefit). The provision for income taxes was $55,000 and $144,000 for the three and nine months ended September 30, 2022, respectively, compared to the benefit for income taxes of $232,000 and $20,000 for the three and nine months ended September 30, 2021, respectively. As a result of the Company having certain net operating losses with an indefinite life under the current federal tax rules, the federal deferred tax liability was offset against the federal net operating loss to the extent allowable in 2022 and 2021. During the quarter ended June 30, 2022, it was determined that for the states that follow the federal rules regarding indefinite life net operating losses, the offset to the state deferred tax liability was $45,000. This amount was recorded during the second quarter of 2022. The current income tax expense for the three and nine months ended September 30, 2022 was approximately $20,000 and $82,000, respectively, and includes state minimum taxes and foreign income taxes. The Company has incurred cumulative losses historically and there is uncertainty regarding future U.S. taxable income, which makes realization of a deferred tax losses difficult to support in accordance with ASC 740. Accordingly, a valuation allowance was recorded against all deferred tax assets at September 30, 2022 and December 31, 2021.

Liquidity and Capital Resources

During the three and nine months ended September 30, 2022, there was positive cash flow from operations of $7.0 million and $15.1 million and at September 30, 2022, the Company had $4.9 million in cash and restricted cash and positive working capital of $5.1 million. The Company has a revolving line of credit with SVB, and, as of September 30, 2022, there was no balance outstanding. During the nine months ended September 30, 2022, the Company sold 1,299,216 shares of 8.75% Series B Preferred Stock and raised $30.3 million in net proceeds after fees and expenses.

The following table summarizes our cash flows for the periods presented:

($ in thousands)

Three Months Ended September 30, 2022 2021 Nine Months Ended September 30, 2022 2021 Change Amount Percent
Net cash provided by operating activities $6,977 $5,129 $15,103 $7,210 $7,893 109%
Net cash used in investing activities (3,496) (2,852) (9,123) (19,851) 10,728 54%
Net cash (used in) provided by financing activities (9,047) (2,319) (11,144) 1,272 (12,416) (976%)
Effect of exchange rate changes on cash 213 (147) (309) (243) (66) (27%)
Net decrease in cash and restricted cash $(5,353) $(189) $(5,473) $(11,612) $6,139 53%

Income before income taxes was $1.1 million and $5.1 million for the three and nine months ended September 30, 2022, which included $2.8 million and $8.7 million of non-cash depreciation and amortization, respectively. The income before income taxes was $1.3 million for the three months ended September 30, 2021, and the loss before income taxes was $706,000 for the nine months ended September 30, 2021, which included $3.5 million and $9.5 million of non-cash depreciation and amortization, respectively.

Operating Activities

Net cash provided by operating activities was $15.1 million and $7.2 million during the nine months ended September 30, 2022 and 2021, respectively. This increase was primarily the result of the increase in net income of $5.6 million which included the following changes in non-cash items: decrease in depreciation and amortization of $733,000, decrease in stock-based compensation of $607,000, and an increase in the change in contingent consideration of $2.9 million.

Accounts receivable decreased by $10,000 for the nine months ended September 30, 2022 compared with an increase of $1.4 million for the nine months ended September 30, 2021. Accounts payable, accrued compensation and accrued expenses decreased by $4.3 million during the nine months ended September 30, 2022 compared with a decrease of $7.0 million for the nine months ended September 30, 2021.

Investing Activities

Net cash used in investing activities was $9.1 million and $19.9 million for the nine months ended September 30, 2022 and 2021, respectively. In 2021, $12.6 million of the $19.9 million of cash used was used for the acquisition of medSR. Capital expenditures were $2.2 million and $2.0 million for the nine months ended September 30, 2022 and 2021, respectively. The capital expenditures for the nine months ended September 30, 2022 and 2021 primarily represented computer equipment purchased and leasehold improvements for the Pakistan Offices. Software development costs of $7.0 million and $5.3 million for the nine months ended September 30, 2022 and 2021, respectively, were capitalized in connection with the development of software for providing technology-enabled business solutions.

Financing Activities

Net cash used in financing activities was $11.1 million during the nine months ended September 30, 2022 and net cash provided by financing activities was $1.3 million during the nine months ended September 30, 2021. The Company received net proceeds from the sale of Series B Preferred Stock of $30.3 million of which $20.0 million was used to redeem 800,000 shares of Series A Preferred Stock. Cash used in financing activities during the nine months ended September 30, 2022 included $11.5 million of preferred stock dividends, $769,000 of repayments for debt obligations and $1.1 million of tax withholding obligations paid in connection with stock awards issued to employees. Cash used in financing activities for the nine months ended September 30, 2021 included $10.8 million of preferred stock dividends, $745,000 of repayment for debt obligations and $2.1 million of tax withholding obligations paid in connection with stock awards issued to employees.

Contractual Obligations and Commitments

We have contractual obligations under our line of credit. We were in compliance with all SVB covenants as of September 30, 2022. We also maintain operating leases for property and certain office equipment. For additional information, see Contractual Obligations and Commitments under Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on March 14, 2022.

Off-Balance Sheet Arrangements

As of September 30, 2022, and 2021, we did not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or special-purpose entities, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. During the first quarter of 2020, a New Jersey corporation, talkMD Clinicians, PA (“talkMD”), was formed by the wife of the Executive Chairman, who is a licensed physician, to provide telehealth services. talkMD was determined to be a variable interest entity (“VIE”) for financial reporting purposes because the entity will be controlled by the Company. As of September 30, 2022, talkMD had not yet commenced operations.

Market risk

As filed, 175 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

We are a smaller reporting company as defined by 17 C.F.R. 229.10(f)(1) and are not required to provide information under this item, pursuant to Item 305(e) of Regulation S-K.

Controls and procedures

As filed, 2,186 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, based on the 2013 framework and criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2022 as required by Rules 13a-15(b) and 15d-15(b) of the Exchange Act. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officer, to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Based on the evaluation of our disclosure controls and procedures, as of September 30, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and l5d-15(f) of the Exchange Act) that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Risk factors

As filed, 685 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the factors discussed in Part I—Item 1A. “Risk Factors” in our Annual Report on Form 10-K, filed with the SEC on March 14, 2022, which could materially affect our business, financial condition and/or future results and may be further impacted by the coronavirus pandemic. The risks described in our Annual Report on Form 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows and/or future results.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-07-01 to 2022-09-30$33.7mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue9 months2022-01-01 to 2022-09-30$106.3mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Research and development3 months2022-07-01 to 2022-09-30$1.2mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2022-01-01 to 2022-09-30$3.3mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-07-01 to 2022-09-30$1.7mus-gaap:OperatingIncomeLoss
Operating income9 months2022-01-01 to 2022-09-30$5.7mus-gaap:OperatingIncomeLoss
Income tax3 months2022-07-01 to 2022-09-30$55.0kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2022-01-01 to 2022-09-30$144.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2022-07-01 to 2022-09-30$1.1mus-gaap:NetIncomeLoss
Net income9 months2022-01-01 to 2022-09-30$4.9mus-gaap:NetIncomeLoss
Basic EPS3 months2022-07-01 to 2022-09-30−$0.18us-gaap:EarningsPerShareBasic
Basic EPS9 months2022-01-01 to 2022-09-30−$0.45us-gaap:EarningsPerShareBasic
Operating cash flow9 months2022-01-01 to 2022-09-30$15.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2022-01-01 to 2022-09-30$2.2mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-09-30$3.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-09-30$29.7mus-gaap:AssetsCurrent
Total assetsAt period end2022-09-30$131.2mus-gaap:Assets
Current liabilitiesAt period end2022-09-30$24.6mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-09-30$28.4mus-gaap:Liabilities
Shareholders' equityAt period end2022-09-30$102.8mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001493152-22-030349. Last ingested by Listed: Nov 5, 2026, 18:58 ET. Listed shows no prices and gives no investment advice.